Clinical trials of viral therapy for malignant gliomas
暂无分享,去创建一个
[1] A. Friedman,et al. 107 Dose-Finding and Safety Study of an Oncolytic Polio/Rhinovirus Recombinant Against Recurrent Glioblastoma , 2013 .
[2] N. Senzer,et al. OPTiM: A randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocyte-macrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] H. Wakimoto,et al. Combination of oncolytic herpes simplex viruses armed with angiostatin and IL-12 enhances antitumor efficacy in human glioblastoma models. , 2013, Neoplasia.
[4] A. Friedman,et al. Dose-finding and safety study of an oncolytic polio/rhinovirus recombinant against recurrent glioblastoma. , 2013 .
[5] P. Lowenstein,et al. Safety profile, efficacy, and biodistribution of a bicistronic high-capacity adenovirus vector encoding a combined immunostimulation and cytotoxic gene therapy as a prelude to a phase I clinical trial for glioblastoma. , 2013, Toxicology and applied pharmacology.
[6] Weiwu Wang,et al. Suppression of Autophagy Enhanced Growth Inhibition and Apoptosis of Interferon-β in Human Glioma Cells , 2013, Molecular Neurobiology.
[7] J. Sarkaria,et al. Oncolytic measles virus strains have significant antitumor activity against glioma stem cells , 2012, Gene Therapy.
[8] D. Lohse,et al. Design and selection of Toca 511 for clinical use: modified retroviral replicating vector with improved stability and gene expression. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.
[9] E. Chiocca,et al. Antitumor efficacy of 34.5ENVE: a transcriptionally retargeted and "Vstat120"-expressing oncolytic virus. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.
[10] Harry E. Gruber,et al. Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector , 2011, Neuro-oncology.
[11] M. von Knebel Doeberitz,et al. Phase I/IIa study of intratumoral/intracerebral or intravenous/intracerebral administration of Parvovirus H-1 (ParvOryx) in patients with progressive primary or recurrent glioblastoma multiforme: ParvOryx01 protocol , 2012, BMC Cancer.
[12] N. Rainov,et al. Clinical development of experimental virus-mediated gene therapy for malignant glioma. , 2011, Anti-cancer agents in medicinal chemistry.
[13] R. Grossman,et al. Phase IB study of gene-mediated cytotoxic immunotherapy adjuvant to up-front surgery and intensive timing radiation for malignant glioma. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] M. Berger,et al. T2 Imaging in Monitoring of Intraparenchymal Real-Time Convection-Enhanced Delivery , 2011, Neurosurgery.
[15] J. Markert,et al. Oncolytic viral therapy of malignant glioma , 2009, Neurotherapeutics.
[16] P. Lowenstein,et al. Gene therapy and targeted toxins for glioma. , 2005, Current gene therapy.
[17] P. Lowenstein,et al. Combined Flt3L/TK gene therapy induces immunological surveillance which mediates an immune response against a surrogate brain tumor neoantigen. , 2011, Molecular Therapy.
[18] J. Fueyo,et al. Eradication of brain tumor stem cells with an oncolytic adenovirus. , 2010, Discovery medicine.
[19] M. Gromeier,et al. Preparing an oncolytic poliovirus recombinant for clinical application against glioblastoma multiforme. , 2010, Cytokine & growth factor reviews.
[20] F. Zemp,et al. Oncolytic viruses as experimental treatments for malignant gliomas: using a scourge to treat a devil. , 2010, Cytokine & growth factor reviews.
[21] F. Lang,et al. Oncolytic adenovirus: preclinical and clinical studies in patients with human malignant gliomas. , 2009, Current gene therapy.
[22] Erwin G. Van Meir,et al. Tumor initiating cells in malignant gliomas: biology and implications for therapy , 2009, Journal of Molecular Medicine.
[23] A. Haseley,et al. Advances in oncolytic virus therapy for glioma. , 2009, Recent patents on CNS drug discovery.
[24] J. Markert,et al. Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.
[25] Raymond D. Harris,et al. Recombinant oncolytic poliovirus eliminates glioma in vivo without genetic adaptation to a pathogenic phenotype. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.
[26] S. Rosenfeld,et al. A Phase I Trial of Ad.hIFN-β Gene Therapy for Glioma. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.
[27] B. Thompson,et al. A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.
[28] E. Galanis,et al. Oncolytic measles virus strains in the treatment of gliomas , 2008, Expert opinion on biological therapy.
[29] H. Colman,et al. Examination of the therapeutic potential of Delta-24-RGD in brain tumor stem cells: role of autophagic cell death. , 2007, Journal of the National Cancer Institute.
[30] J. Sampson,et al. Viruses in the treatment of malignant glioma. , 2007, Expert Review of Neurotherapeutics.
[31] J. Gomori,et al. Phase I/II trial of intravenous NDV-HUJ oncolytic virus in recurrent glioblastoma multiforme. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.
[32] F. McCormick,et al. Late viral RNA export, rather than p53 inactivation, determines ONYX-015 tumor selectivity. , 2004, Cancer cell.
[33] S. Ylä-Herttuala,et al. AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.
[34] J. Olson,et al. A phase I open-label, dose-escalation, multi-institutional trial of injection with an E1B-Attenuated adenovirus, ONYX-015, into the peritumoral region of recurrent malignant gliomas, in the adjuvant setting. , 2004, Molecular therapy : the journal of the American Society of Gene Therapy.
[35] S. Brown,et al. HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival , 2004, Gene Therapy.
[36] B. Bodey,et al. MTH-68/H Oncolytic Viral Treatment in Human High-Grade Gliomas , 2004, Journal of Neuro-Oncology.
[37] I. Germano,et al. Adenovirus/Herpes Simplex-Thymidine Kinase/Ganciclovir Complex: Preliminary Results of a Phase I trial in Patients with Recurrent Malignant Gliomas , 2003, Journal of Neuro-Oncology.
[38] M. Mizuno,et al. IFN-β Gene Therapy Induces Systemic Antitumor Immunity Against Malignant Glioma , 2000, Journal of Neuro-Oncology.
[39] Susan M. Chang,et al. Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] C. Avezaat,et al. Treatment of relapsed malignant glioma with an adenoviral vector containing the herpes simplex thymidine kinase gene followed by ganciclovir. , 2003, Molecular therapy : the journal of the American Society of Gene Therapy.
[41] P. Mishra,et al. Use of a vaccine strain of measles virus genetically engineered to produce carcinoembryonic antigen as a novel therapeutic agent against glioblastoma multiforme. , 2003, Cancer research.
[42] G. Fuller,et al. Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. , 2003, Journal of the National Cancer Institute.
[43] N. Rainov,et al. Gene Therapy for Human Malignant Brain Tumors , 2003, Cancer journal.
[44] R. Petty,et al. The potential for efficacy of the modified (ICP 34.5−) herpes simplex virus HSV1716 following intratumoural injection into human malignant glioma: a proof of principle study , 2002, Gene Therapy.
[45] A. Alavi,et al. Treatment of recurrent or progressive malignant glioma with a recombinant adenovirus expressing human interferon-beta (H5.010CMVhIFN-beta): a phase I trial. , 2001, Human gene therapy.
[46] R. Martuza,et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial , 2000, Gene Therapy.
[47] A. Maclean,et al. Toxicity evaluation of replication-competent herpes simplex virus (ICP 34.5 null mutant 1716) in patients with recurrent malignant glioma , 2000, Gene Therapy.
[48] R. Grossman,et al. Phase I study of adenoviral delivery of the HSV-tk gene and ganciclovir administration in patients with current malignant brain tumors. , 2000, Molecular therapy : the journal of the American Society of Gene Therapy.
[49] M. Mizuno,et al. IFN-beta gene therapy induces systemic antitumor immunity against malignant glioma. , 2000, Journal of neuro-oncology.
[50] T. Bakács,et al. Use of Newcastle disease virus vaccine (MTH-68/H) in a patient with high-grade glioblastoma. , 1999, JAMA.
[51] S. Ylä-Herttuala,et al. Beta-galactosidase gene transfer to human malignant glioma in vivo using replication-deficient retroviruses and adenoviruses. , 1998, Human gene therapy.
[52] J. Trojanowski,et al. Therapy of experimental human brain tumors using a neuroattenuated herpes simplex virus mutant. , 1995, Laboratory investigation; a journal of technical methods and pathology.
[53] R. Martuza,et al. Attenuated multi–mutated herpes simplex virus–1 for the treatment of malignant gliomas , 1995, Nature Medicine.